Cargando…

Crosstalk between gut microbiota and COVID-19 impacts pancreatic cancer progression

Pancreatic cancer (PC) is one of the most common causes of cancer-associated death worldwide, with a low rate of 5-year survival. Currently, the pathogenesis of PC is complicated, with no efficient therapy. Coronavirus disease 2019 (COVID-19) disease caused by severe acute respiratory syndrome coron...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Chun-Ye, Liu, Shuai, Yang, Ming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9412935/
https://www.ncbi.nlm.nih.gov/pubmed/36160747
http://dx.doi.org/10.4251/wjgo.v14.i8.1456
_version_ 1784775615039143936
author Zhang, Chun-Ye
Liu, Shuai
Yang, Ming
author_facet Zhang, Chun-Ye
Liu, Shuai
Yang, Ming
author_sort Zhang, Chun-Ye
collection PubMed
description Pancreatic cancer (PC) is one of the most common causes of cancer-associated death worldwide, with a low rate of 5-year survival. Currently, the pathogenesis of PC is complicated, with no efficient therapy. Coronavirus disease 2019 (COVID-19) disease caused by severe acute respiratory syndrome coronavirus 2 further exacerbates the challenge of patients with PC. The alteration of gut microbiota caused by COVID-19 infection may impact PC progression in patients via immune regulation. The expression of inflammatory immune mediators such as interleukin (IL)-6, IL-8, and IL-10 has been found to increase in both PC and COVID-19 patients, which is associated with the disease severity and prognostic outcome. Gut microbiome serves as a critical connector between viral infection and PC. It can regulate host systemic immune response and impact the efficacy of immunotherapy. Here, we first demonstrated the features of inflammatory cytokines in both diseases and their impact on disease outcomes. Then, we demonstrated the importance of immunotherapeutic strategies. This includes the immune modulation that targets a single or dual receptors using a single agent or their combinations for the treatment of PC in patients who get infected with COVID-19. Additionally, we explored the possibility of managing the disease by regulating gut microbiome. Overall, modulation of the lung-gut-pancreases axis can boost anti-cancer immunotherapy and reduce adverse prognostic outcomes.
format Online
Article
Text
id pubmed-9412935
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-94129352022-09-23 Crosstalk between gut microbiota and COVID-19 impacts pancreatic cancer progression Zhang, Chun-Ye Liu, Shuai Yang, Ming World J Gastrointest Oncol Minireviews Pancreatic cancer (PC) is one of the most common causes of cancer-associated death worldwide, with a low rate of 5-year survival. Currently, the pathogenesis of PC is complicated, with no efficient therapy. Coronavirus disease 2019 (COVID-19) disease caused by severe acute respiratory syndrome coronavirus 2 further exacerbates the challenge of patients with PC. The alteration of gut microbiota caused by COVID-19 infection may impact PC progression in patients via immune regulation. The expression of inflammatory immune mediators such as interleukin (IL)-6, IL-8, and IL-10 has been found to increase in both PC and COVID-19 patients, which is associated with the disease severity and prognostic outcome. Gut microbiome serves as a critical connector between viral infection and PC. It can regulate host systemic immune response and impact the efficacy of immunotherapy. Here, we first demonstrated the features of inflammatory cytokines in both diseases and their impact on disease outcomes. Then, we demonstrated the importance of immunotherapeutic strategies. This includes the immune modulation that targets a single or dual receptors using a single agent or their combinations for the treatment of PC in patients who get infected with COVID-19. Additionally, we explored the possibility of managing the disease by regulating gut microbiome. Overall, modulation of the lung-gut-pancreases axis can boost anti-cancer immunotherapy and reduce adverse prognostic outcomes. Baishideng Publishing Group Inc 2022-08-15 2022-08-15 /pmc/articles/PMC9412935/ /pubmed/36160747 http://dx.doi.org/10.4251/wjgo.v14.i8.1456 Text en ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
spellingShingle Minireviews
Zhang, Chun-Ye
Liu, Shuai
Yang, Ming
Crosstalk between gut microbiota and COVID-19 impacts pancreatic cancer progression
title Crosstalk between gut microbiota and COVID-19 impacts pancreatic cancer progression
title_full Crosstalk between gut microbiota and COVID-19 impacts pancreatic cancer progression
title_fullStr Crosstalk between gut microbiota and COVID-19 impacts pancreatic cancer progression
title_full_unstemmed Crosstalk between gut microbiota and COVID-19 impacts pancreatic cancer progression
title_short Crosstalk between gut microbiota and COVID-19 impacts pancreatic cancer progression
title_sort crosstalk between gut microbiota and covid-19 impacts pancreatic cancer progression
topic Minireviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9412935/
https://www.ncbi.nlm.nih.gov/pubmed/36160747
http://dx.doi.org/10.4251/wjgo.v14.i8.1456
work_keys_str_mv AT zhangchunye crosstalkbetweengutmicrobiotaandcovid19impactspancreaticcancerprogression
AT liushuai crosstalkbetweengutmicrobiotaandcovid19impactspancreaticcancerprogression
AT yangming crosstalkbetweengutmicrobiotaandcovid19impactspancreaticcancerprogression